The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.
 
Toshio Shimizu
Honoraria - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - CHAIR; Takeda
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - 3D Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); SymBio Pharmaceuticals (Inst); Takeda/Millennium (Inst)
Travel, Accommodations, Expenses - Takeda
 
Yutaka Fujiwara
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Kan Yonemori
Honoraria - Eisai; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai
 
Takafumi Koyama
Consulting or Advisory Role - Astellas Amgen Biopharma
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan
Research Funding - Novartis (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Jun Sato
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Hiroki Ikezawa
Employment - Eisai
 
Maiko Nomoto
Employment - Eisai
 
Ryo Nakajima
Employment - Eisai
 
Takuma Miura
Employment - Eisai
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)